HUMA — Humacyte, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-12-01.
Performance
Technicals
Others in Healthcare
Measured signals that fired on HUMA
| date | signal | measured base rate |
|---|---|---|
| 2026-05-29 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-20 | Jones Keith Anthony Director | Open-market purchase | 10.0K | 0.69 | 6.9K |
| 2026-08-17 | Jones Keith Anthony Director | Open-market purchase | 30.0K | 0.59 | 17.8K |
| 2026-05-19 | Sebelius Kathleen Director | Open-market purchase | 56.8K | 0.88 | 50.0K |
| 2026-05-18 | Parikh Shamik J Chief Medical Officer | Open-market sale 10b5-1 plan | 45.9K | 0.90 | 41.1K |
| 2026-05-18 | Sander Dale A. CFO and Chief Corp. Dev. Off | Open-market sale 10b5-1 plan | 45.9K | 0.90 | 41.1K |
| 2026-05-18 | Constantino Michael T. Director | Open-market purchase | 11.0K | 0.89 | 9.8K |
| 2025-11-16 | Parikh Shamik J Chief Medical Officer | Grant or award | 311.1K | 0.00 | 0 |
| 2025-11-16 | Sander Dale A. CFO and Chief Corp. Deve. Off. | Grant or award | 311.1K | 0.00 | 0 |
| 2025-08-20 | Niklason Laura E President, CEO and Director | Open-market sale | 591.7K | 1.58 | 934.9K |
| 2025-08-20 | Dougan Brady W Director | Open-market sale | 591.7K | 1.58 | 934.9K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 7.5M | 12.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3M | 7.2M |
| ANTIPODES PARTNERS Ltd | 3.5M | 5.7M |
| GREAT POINT PARTNERS LLC | 2.3M | 3.8M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2M | 3.7M |
| STATE STREET CORP | 1.8M | 3.0M |
| UBS Group AG | 1.7M | 2.8M |
| Woodline Partners LP | 1.2M | 2.0M |
| AQR CAPITAL MANAGEMENT LLC | 1.2M | 1.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 860.6K | 1.4M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA · 2026-08-22
- Humacyte shares fall after Q2 revenue, EPS miss · 2026-08-12
- Humacyte GAAP EPS of -$0.16 misses by $0.06, revenue of $0.41M misses by $0.7M · 2026-08-12
- Humacyte, Inc. (HUMA) filed form 8-K · 2026-08-12 · SEC EDGAR
Ask the AI about HUMA
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →